’t Hart, B. A. et al. (2017) ‘A B cell-driven autoimmune pathway leading to pathological hallmarks of progressive multiple sclerosis in the marmoset experimental autoimmune encephalomyelitis model’, Frontiers in Immunology, 8(JUL), pp. 1–14. doi: 10.3389/fimmu.2017.00804.
Adzemovic, M. Z. et al. (2013) ‘Efficacy of vitamin D in treating multiple sclerosis-like neuroinflammation depends on developmental stage’, Experimental Neurology, 249, pp. 39–48. doi: 10.1016/j.expneurol.2013.08.002.
Arneth, B. M. (2019) ‘Impact of B cells to the pathophysiology of multiple sclerosis’, Journal of Neuroinflammation. Journal of Neuroinflammation, 16(1), pp. 1–9. doi: 10.1186/s12974-019-1517-1.
Barun, B. and Bar-Or, A. (2012) ‘Treatment of multiple sclerosis with Anti-CD20 antibodies’, Clinical Immunology. Elsevier Inc., 142(1), pp. 31–37. doi: 10.1016/j.clim.2011.04.005.
Blauth, K. et al. (2015) ‘Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants’, Acta Neuropathologica, 130(6), pp. 765–781. doi: 10.1007/s00401-015-1500-6.
Bouaziz, J. D. et al. (2007) ‘Therapeutic B cell depletion impairs adaptive and autoreactive CD4 + T cell activation in mice’, Proceedings of the National Academy of Sciences of the United States of America, 104(52), pp. 20878–20883. doi: 10.1073/pnas.0709205105.
Claes, N. et al. (2015) ‘B cells are multifunctional players in multiple sclerosis pathogenesis: Insights from therapeutic interventions’, Frontiers in Immunology, 6(DEC). doi: 10.3389/fimmu.2015.00642.
Faissner, S. et al. (2019) ‘Progressive multiple sclerosis: from pathophysiology to therapeutic strategies’, Nature Reviews Drug Discovery. Springer US, 18(12), pp. 905–922. doi: 10.1038/s41573-019-0035-2.
Helliwell, C. L. and Coles, A. J. (2009) ‘Monoclonal antibodies in multiple sclerosis treatment: Current and future steps’, Therapeutic Advances in Neurological Disorders, 2(4), pp. 195–203. doi: 10.1177/1756285609337827.
Johnston, S. L. and Hollingsworth, R. (2016) ‘Immunoglobulin therapy’, Clinical Medicine, Journal of the Royal College of Physicians of London, 16(6), pp. 576–579. doi: 10.7861/clinmedicine.16-6-576.
Kap, Y. S., Laman, J. D. and ‘t Hart, B. A. (2010) ‘Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development’, Journal of Neuroimmune Pharmacology, 5(2), pp. 220–230. doi: 10.1007/s11481-009-9178-y.
Korhonen, R. and Moilanen, E. (2010) ‘Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis’, Basic and Clinical Pharmacology and Toxicology, 106(1), pp. 13–21. doi: 10.1111/j.1742-7843.2009.00452.x.
Mann, M. K. et al. (2012) ‘Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis’, Autoimmunity, 45(5), pp. 388–399. doi: 10.3109/08916934.2012.665523.
Matsushita, T. et al. (2008) ‘Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression’, Journal of Clinical Investigation, 118(10), pp. 3420–3430. doi: 10.1172/JCI36030.
Meffre, E. and O’Connor, K. C. (2019) ‘Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies’, Immunological Reviews, 292(1), pp. 90–101. doi: 10.1111/imr.12821.
Monson, N. L. et al. (2011) ‘Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis’, PLoS ONE, 6(2), pp. 1–6. doi: 10.1371/journal.pone.0017103.
O’Neill, S. K., Glant, T. T. and Finnegan, A. (2007) ‘The role of B cells in animal models of rheumatoid arthritis’, Frontiers in Bioscience, 12, pp. 1722–1736. Available at: http://ci.nii.ac.jp/naid/40015195484/en/.
Staun-Ram, E. and Miller, A. (2017) ‘Effector and regulatory B cells in Multiple Sclerosis’, Clinical Immunology. Elsevier Inc., 184, pp. 11–25. doi: 10.1016/j.clim.2017.04.014.
Ücal, M. et al. (2017) ‘Widespread cortical demyelination of both hemispheres can be induced by injection of pro-inflammatory cytokines via an implanted catheter in the cortex of MOG-immunized rats’, Experimental Neurology. Elsevier Inc., 294, pp. 32–44. doi: 10.1016/j.expneurol.2017.04.014.
Weber, M. S. et al. (2010) ‘B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity’, Annals of Neurology, 68(3), pp. 369–383. doi: 10.1002/ana.22081.